文献速递核素与放射性配体治疗放射性药物与辐射防护

转移性去势抵抗性前列腺癌患者中177Lu-PSMA-617的肾脏及多器官安全性:VISION剂量学子研究

Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
PubMed 文献 · J Nucl Med · 2024-01-02

VISION剂量学子研究纳入30例非随机接受标准治疗联合177Lu-PSMA-617(每周期7.4 GBq,最多6周期)的转移性去势抵抗性前列腺癌患者,量化肾脏和其他器官的吸收剂量。肾脏每周期平均吸收剂量为第1周期0.43±0.16 Gy/GBq、第2-6周期0.44±0.21 Gy/GBq,观察与预测的6周期累积肾脏吸收剂量分别为15±6 Gy和19±7 Gy。结论认为肾脏累积吸收剂量低于既定限值,整体安全性良好,低肾脏放射性毒性不是安全性问题。

要点

  • 肾脏每周期平均吸收剂量:第1周期0.43±0.16 Gy/GBq,第2-6周期0.44±0.21 Gy/GBq。
  • 观察与预测的6周期累积肾脏吸收剂量分别为15±6 Gy和19±7 Gy。
  • 无患者发生高于3级的肾脏治疗中出现的不良事件。

核心结论

  • 177Lu-PSMA-617的肾脏累积吸收剂量低于既定限值,整体安全性良好,低肾脏放射性毒性不是安全性问题。
  • 在转移性去势抵抗性前列腺癌患者中,多周期高危器官累积吸收剂量可通过第1周期数据外推预测。

研究设计与样本

  • VISION剂量学子研究为30例非随机患者组成的独立队列,接受标准治疗联合177Lu-PSMA-617每周期7.4 GBq、最多6周期。
  • 采集血样、全身共轭平面显像和腹部SPECT/CT图像;第1周期给药后2、24、48和168小时采集SPECT/CT,第2-6周期仅在给药后48小时单时间点采集。
  • 结局为每周期每单位活度的吸收剂量及所有周期累积吸收剂量;累积吸收剂量通过第1周期外推预测,并基于第1周期和第2-6周期测量计算观察值;同时评估安全性。

主要发现

  • 肾脏每周期平均(±SD)吸收剂量:第1周期0.43±0.16 Gy/GBq,第2-6周期0.44±0.21 Gy/GBq。
  • 观察与预测的6周期累积肾脏吸收剂量分别为15±6 Gy和19±7 Gy。
  • 其他高危器官的观察与预测累积吸收剂量相似。
  • 安全性结果与VISION研究一致;无患者发生高于3级的肾脏治疗中出现的不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the VISION trial, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) plus protocol-permitted standard of care significantly improved overall survival and radiographic progression-free survival compared with standard of care alone in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. This VISION dosimetry substudy quantified absorbed doses of 177Lu-PSMA-617 in the kidneys and other organs. Methods: Participants were a separate cohort of 30 nonrandomized patients receiving standard of care plus 177Lu-PSMA-617 at 7.4 GBq per cycle for up to 6 cycles. Blood samples, whole-body conjugate planar image scintigraphy, and abdominal SPECT/CT images were collected. SPECT/CT images were collected at 2, 24, 48, and 168 h after administration in cycle 1 and at a single time point 48 h after administration in cycles 2-6. Outcomes were absorbed dose per unit activity per cycle and cumulative absorbed dose over all cycles. Cumulative absorbed doses were predicted by extrapolation from cycle 1, and calculation of observed values was based on measurements of cycle 1 and cycles 2-6. Safety was also assessed. Results: Mean (±SD) absorbed doses per cycle in the kidneys were 0.43 ± 0.16 Gy/GBq in cycle 1 and 0.44 ± 0.21 Gy/GBq in cycles 2-6. The observed and predicted 6-cycle cumulative absorbed doses in the kidneys were 15 ± 6 and 19 ± 7 Gy, respectively. Observed and predicted cumulative absorbed doses were similar in other at-risk organs. Safety findings were consistent with those in the VISION study; no patients experienced renal treatment-emergent adverse events of a grade higher than 3. Conclusion: The renal cumulative absorbed 177Lu-PSMA-617 dose was below the established limit. 177Lu-PSMA-617 had a good overall safety profile, and low renal radiotoxicity was not a safety concern. Cumulative absorbed doses in at-risk organs over multiple cycles can be predicted by extrapolation from cycle 1 data in patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Herrmann K, Rahbar K, Eiber M, et al. Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy. J Nucl Med. 2024. PMID: 38050121. doi:10.2967/jnumed.123.265448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。